Background and Aim: Macrophage inhibitory cytokine (MIC-1) and tissue polypeptide-specific antigen (TPS) are novel markers for several inflammatory and malignant disorders, and there are no sufficient data about the utility of these antigens as serum tumor markers. We aimed at measuring the serum levels of MIC-1 and TPS in patients with benign and malignant pancreatobiliary diseases and at determining their diagnostic efficacy. Patients and Methods: Sera collected from patients with pancreatic adenocarcinomas (56 cases), periampullary carcinomas other than pancreatic carcinomas (15 cases), benign pancreatic diseases (31 cases), benign biliary diseases (15 cases) and healthy volunteers (33 cases) were analyzed for MIC-1 and TPS and the results were compared with CA 19-9. Results: Serum MIC-1 levels increased more significantly in patients with pancreatic carcinomas than in patients with benign pancreatobiliary diseases and healthy controls (p < 0.05). MIC-1 has a similar sensitivity (81%) but a lower specificity (73 vs. 97%) than CA 19-9 in patients with pancreatic carcinomas. Serum TPS was comparable among patients with malignant and benign pancreatobiliary diseases, and healthy controls. Conclusion: MIC-1 is a valuable tumor marker for the diagnosis of pancreatic cancer. It has a good correlation with CA 19-9. TPS has no diagnostic importance to differentiate pancreatobiliary diseases.

1.
Bootcov MR, Bauskin AR, Valenzuela SM, et al: MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-β superfamily cluster. Proc Natl Acad Sci USA 1997;94:11514–11519.
2.
Wiklund FE, Bennet AM, Magnusson PK, et al: Macrophage inhibitory cytokine-1 (MIC-1/GDF15): a new marker of all-cause mortality. Aging Cell 2010;9:1057–1064.
3.
Ding Q, Mracek T, Gonzalez-Muniesa P, et al: Identification of macrophage inhibitory cytokine-1 in adipose tissue and its secretion as an adipokine by human adipocytes. Endocrinology 2009;150:1688–1696.
4.
Böttner M, Suter-Crazzolara C, Schober A, et al: Expression of a novel member of the TGF-β superfamily, growth/differentiation factor-15/macrophage-inhibiting cytokine-1 (GDF-15/MIC-1) in adult rat tissues. Cell Tissue Res 1999;297:103–110.
5.
Schober A, Böttner M, Strelau J, et al: Expression of growth differentiation factor-15/macrophage inhibitory cytokine-1 (GDF-15/MIC-1) in the perinatal, adult, and injured rat brain. J Comp Neurol 2001;439:32–45.
6.
Fairlie WD, Moore AG, Bauskin AR, et al: MIC-1 is a novel TGF-h superfamily cytokine associated with macrophage activation. J Leukocyte Biol 1999;65:2–5.
7.
Brown DA, Ward RL, Buckhaults P, et al: MIC-1 serum level and genotype: associations with progress and prognosis of colorectal carcinoma. Clin Cancer Res 2003;9:2642–2650.
8.
Brown DA, Ward RL, Buckhaults P, et al: MIC-1 serum level and genotype: associations with progress and prognosis of colorectal carcinoma. Clin Cancer Res 2003;9:2642–2650.
9.
Wollmann W, Goodman ML, Bhat-Nakshatri P, et al: The macrophage inhibitory cytokine integrates AKT/PKB and MAP kinase signaling pathways in breast cancer cells. Carcinogenesis 2005;26:900–907.
10.
Bauskin AR, Brown DA, Kuffner T, et al: Role of macrophage inhibitory cytokine-1 in tumorigenesis and diagnosis of cancer. Cancer Res 2006;66:4983–4986.
11.
Nakamura T, Scorilas A, Stephan C, et al: Quantitative analysis of macrophage inhibitory cytokine-1 gene expression in human prostatic tissues. Br J Cancer 2003;88:1101–1104.
12.
Koopmann J, Rosenzweig CN, Zhang Z, et al: Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA 19-9. Clin Cancer Res 2006;12:442–446.
13.
Koopmann J, Buckhaults P, Brown DA, et al: Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clin Cancer Res 2004;10:2386–2392.
14.
Kornek G, Schenk T, Raderer M, et al: Tissue polypeptide-specific antigen in monitoring palliative treatment response of patients with gastrointestinal tumours. Br J Cancer 1995;71:182–185.
15.
Glimelius B, Hoffman K, Einarsson R, et al: Monitoring palliative chemotherapy in advanced gastrointestinal cancer using serial tissue polypeptide-specific antigen measurements. Acta Oncol 1996;35:141–148.
16.
Pasanen PA, Eskelinen M, Partanen K, et al: A prospective study of serum tumour markers carcinoembryonic antigen, carbohydrate antigens 50 and 242, tissue polypeptide antigen and tissue polypeptide-specific antigen in the diagnosis of pancreatic cancer with special reference to multivariate diagnostic score. Br J Cancer 1994;69:562–565.
17.
Banfi G, Zerbi A, Pastori S, et al: Behavior of tumor markers CA19.9, CA195, CAM43, CA242, and TPS in the diagnosis and follow-up of pancreatic cancer. Clin Chem 1993;39:420–423.
18.
Slesak B, Harlozinska-Szmyrka A, Knast W, et al: TPS and CA 19-9 measurements in the follow-up of patients with pancreatic cancer and chronic pancreatitis. Int J Biol Markers 2004;19:115–119.
19.
Slesak B, Harlozinska-Szmyrka A, Knast W, et al: Tissue polypeptide-specific antigen, a marker for differentiation between pancreatic carcinoma and chronic pancreatitis. A comparative study with CA 19-9. Cancer 2000;89:83–88.
20.
Ohkawara T, Nishihira J, Takeda H, et al: Pathophysiological roles of macrophage migration inhibitory factor in gastrointestinal, hepatic, and pancreatic disorders. J Gastroenterol 2005;40:117–122.
21.
Johansson U, Olsson A, Gabrielsson S, et al: Inflammatory mediators expressed in human islets of Langerhans: implications for islet transplantation. Biochem Biophys Res Commun 2003;308:474–479.
22.
Waeber G, Calandra T, Roduit R, et al: Insulin secretion is regulated by the glucose-dependent production of islet β-cell macrophage migration inhibitory factor. Proc Natl Acad Sci USA 1997;94:4782–4787.
23.
Sakai Y, Masamune A, Satoh A, et al: Macrophage migration inhibitory factor is a critical mediator of severe acute pancreatitis. Gastroenterology 2003;124:725–736.
24.
Rahman SH, Menon KV, Holmfield JH, et al: Serum macrophage migration inhibitory factor is an early marker of pancreatic necrosis in acute pancreatitis. Ann Surg 2007;245:282–289.
25.
Golkar L, Ding XZ, Ujiki MB, et al: Resveratrol inhibits pancreatic cancer cell proliferation through transcriptional induction of macrophage inhibitory cytokine-1. J Surg Res 2007;138:163–169.
26.
Ozkan H, Akat T, Köklü S, et al: Significance of serum receptor-binding cancer antigen (RCAS1) in pancreatic cancer and benign pancreatobiliary diseases. Pancreatology 2006;6:268–272.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.